Table 1 Patient demographics and baseline characteristics
Characteristics | Arm A | Arm B | Arm C | All patients |
|---|---|---|---|---|
Motesanib | Motesanib | Motesanib | ||
125 mg QD | 75 mg BID 2 wk on/1 wk off | 75 mg BID 5 d on/2 d off | ||
n = 25 | n = 12 | n = 12 | N = 49 | |
Sex, n (%) | ||||
Women | 10 (40) | 6 (50) | 5 (42) | 21 (43) |
Men | 15 (60) | 6 (50) | 7 (58) | 28 (57) |
Race, n (%) | ||||
White | 22 (88) | 11 (92) | 11 (92) | 44 (90) |
Black | 2 (8) | 0 (0) | 0 (0) | 2 (4) |
Hispanic | 1 (4) | 1 (8) | 0 (0) | 2 (4) |
Native Hawaiian or other Pacific Islander | 0 (0) | 0 (0) | 1 (8) | 1 (2) |
Median age (range), y | 59 (28–70) | 52 (30–70) | 59 (22–81) | 58 (22–81) |
Age group, n (%) | ||||
<65 y | 18 (72) | 10 (83) | 9 (75) | 37 (76) |
≥65 y | 7 (28) | 2 (17) | 3 (25) | 12 (24) |
≥75 y | 0 (0) | 0 (0) | 1 (8) | 1 (2) |
Tumor type, n (%) | ||||
Thyroid | 1 (4) | 7 (58) | 4 (33) | 12 (24) |
Colon | 3 (12) | 0 (0) | 1 (8) | 4 (8) |
Non–small-cell lung | 3 (12) | 0 (0) | 1 (8) | 4 (8) |
Carcinoma of unknown origin | 1 (4) | 1 (8) | 0 (0) | 2 (4) |
Cervix | 1 (4) | 0 (0) | 1 (8) | 2 (4) |
Oral | 1 (4) | 0 (0) | 1 (8) | 2 (4) |
Ovarian | 1 (4) | 0 (0) | 1 (8) | 2 (4) |
Small-cell lung | 0 (0) | 2 (17) | 0 (0) | 2 (4) |
Soft tissue sarcoma | 1 (4) | 0 (0) | 1 (8) | 2 (4) |
Bile duct | 1 (4) | 0 (0) | 0 (0) | 1 (2) |
Bone sarcoma | 1 (4) | 0 (0) | 0 (0) | 1 (2) |
Esophageal | 1 (4) | 0 (0) | 0 (0) | 1 (2) |
Kidney | 1 (4) | 0 (0) | 0 (0) | 1 (2) |
Liver | 1 (4) | 0 (0) | 0 (0) | 1 (2) |
Squamous cell carcinoma of head and neck | 1 (4) | 0 (0) | 0 (0) | 1 (2) |
Other | 7 (28) | 2 (17) | 2 (17) | 11 (22) |
ECOG performance status, n (%) | ||||
0 | 14 (56) | 8 (67) | 9 (75) | 31 (63) |
1 | 10 (40) | 4 (33) | 3 (25) | 17 (35) |
2 | 1 (4) | 0 (0) | 0 (0) | 1 (2) |
Disease stage, n (%) | ||||
Stage III | 1 (4) | 0 (0) | 0 (0) | 1 (2) |
Stage IV | 22 (88) | 11 (92) | 11 (92) | 44 (90) |
Unknown | 2 (8) | 1 (8) | 1 (8) | 4 (8) |
Number of sites of disease,* n (%) | ||||
0 | 1 (4) | 0 (0) | 1 (8) | 2 (4) |
1 | 13 (52) | 4 (33) | 3 (25) | 20 (41) |
2 | 10 (40) | 5 (42) | 6 (50) | 21 (43) |
≥3 | 1 (4) | 3 (25) | 2 (17) | 6 (50) |
Number of prior therapies,† n (%) | ||||
0 | 5 (20) | 1 (8) | 1 (8) | 7 (14) |
1 | 5 (20) | 1 (8) | 2 (17) | 8 (16) |
2 | 2 (8) | 1 (8) | 3 (25) | 6 (12) |
≥3 | 13 (52) | 9 (75) | 6 (50) | 28 (57) |
Alcohol use, n (%) | ||||
Never | 1 (4) | 5 (42) | 4 (33) | 10 (20) |
Former | 5 (20) | 1 (8) | 2 (17) | 8 (16) |
Current | 18 (72) | 5 (42) | 5 (42) | 28 (57) |
Missing | 1 (4) | 1 (8) | 1 (8) | 3 (6) |